Efficacy and Safety of Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT 2)

Brief description of study

This is a study of an investigational drug (also known as the “study drug”) called Peginterferon Lambda-1a (Lambda) as a possible treatment for chronic hepatitis delta virus (HDV) infection. An investigational drug has not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies for clinical use. This study involves research on the potential benefits of Lambda for the treatment of chronic HDV infection.

Lambda is given by subcutaneous (SC) injection, meaning that it is injected under the skin, once a week for up to 48 weeks. The main purpose of this study is to see if once weekly Lambda SC injections given for up to 48 weeks can help to treat chronic HDV infection

Clinical Study Identifier: s22-00048

Principal Investigator: Ira M. Jacobson.

Other Investigator: Mary Christine Olson.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies